International expert consensus recommendations for the use of dermocosmetics in acne

Diane Thiboutot(Penn State Milton S. Hershey Medical Center), Brigitte Dréno(Nantes Université), Gabriel Gontijo, Ibrahima Traore(Gamal Abdel Nasser University of Conakry), Alison Layton(University of York), Patricia Troielli(Universidad de Buenos Aires), Qiang Ju(Renji Hospital), Ichiro Kurokawa(Hyogo Prefectural Nishinomiya Hospital)
Journal of the European Academy of Dermatology and Venereology
June 15, 2024
10.1111/jdv.20145
Cited by 26

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|981